AZ presents strong H1 financial results
admin 29th July 2019 Uncategorised 0The sales numbers were boosted by oncology drugs such as Tagrisso, Imfinzi and Lynparza. More: AZ presents strong H1 financial results Source: News
read moreThe sales numbers were boosted by oncology drugs such as Tagrisso, Imfinzi and Lynparza. More: AZ presents strong H1 financial results Source: News
read moreThe drug is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator. More: Janssen’s ponesimod holds up against Aubagio in late-stage trial Source: News
read moreScientists are “re-imagining ultrasound technology to develop a treatment that can liquefy cancer cells in the body using microscopic bubbles”. More: First convergent science centre launched in UK Source: News
read moreThe application is for cabotegravir and Edurant (rilpivirine) as the first monthly, injectable treatment for HIV. More: ViiV submits regulatory application to EMA for investigational HIV combo Source: News
read moreRates have increased by more than a third (35%) for women and by almost three-fifths (55%) for men. More: Skin cancer rates rocket 45% in 10 years Source: News
read moreFor Pfizer’s blockbuster immunology drug Xeljanz, an FDA safety communication has now turned into a boxed warning. And forget the drug’s approval as a first-line ulcerative colitis treatment, at least for now. More: Red flag upgrade for Pfizer: FDA limits
read more© 1994 - 2024 B.M. Pharmaceuticals